Literature DB >> 25282363

Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial.

G Scantamburlo1, M Hansenne2, V Geenen3, J J Legros4, M Ansseau5.   

Abstract

The aim of this open trial was to assess the antidepressant/anxiolytic effects of oxytocin used as an adjunct to antidepressant in treatment-resistant depression. Fourteen patients, who have not responded to 40mg of escitalopram, received intranasal synthetic oxytocin during 4 weeks, in association with antidepressant. This is the first open trial study suggesting OT in association with escitalopram significantly reduced scores on Hamilton Depression Rating Scale.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anxiety; Intranasal oxytocin; Major depression

Mesh：

Substances：

Year:  2014        PMID： 25282363     DOI： 10.1016/j.eurpsy.2014.08.007

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN： 0924-9338            Impact factor:   5.361


  14 in total

Review 1.  Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome.

Authors:  Teodor T Postolache; Laura Del Bosque-Plata; Serge Jabbour; Michael Vergare; Rongling Wu; Claudia Gragnoli
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2019-02-06       Impact factor: 3.568

2.  Computational Analysis of Therapeutic Neuroadaptation to Chronic Antidepressant in a Model of the Monoaminergic Neurotransmitter and Stress Hormone Systems.

Authors:  Mariam B Camacho; Warut D Vijitbenjaronk; Thomas J Anastasio
Journal:  Front Pharmacol       Date:  2019-10-25       Impact factor: 5.810

3.  Low Fasting Oxytocin Levels Are Associated With Psychopathology in Anorexia Nervosa in Partial Recovery.

Authors:  Yuliya Afinogenova; Cindy Schmelkin; Franziska Plessow; Jennifer J Thomas; Reitumetse Pulumo; Nadia Micali; Karen K Miller; Kamryn T Eddy; Elizabeth A Lawson
Journal:  J Clin Psychiatry       Date:  2016-11       Impact factor: 4.384

4.  Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review.

Authors:  Marilyn Horta; Kathryn Kaylor; David Feifel; Natalie C Ebner
Journal:  Neurosci Biobehav Rev       Date:  2019-10-21       Impact factor: 8.989

Review 5.  The Neuropeptide Hormone Oxytocin in Eating Disorders.

Authors:  Franziska Plessow; Kamryn T Eddy; Elizabeth A Lawson
Journal:  Curr Psychiatry Rep       Date:  2018-09-04       Impact factor: 5.285

Review 6.  Metabolic Effects of Oxytocin.

Authors:  Shana E McCormack; James E Blevins; Elizabeth A Lawson
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

7.  Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression?

Authors:  Yusuke Miwa; Hidekazu Furuya; Ryo Yanai; Tsuyoshi Kasama; Kenji Sanada
Journal:  Eur J Rheumatol       Date:  2018-01-22

8.  The combination of fluoxetine and environmental enrichment reduces postpartum stress-related behaviors through the oxytocinergic system and HPA axis in mice.

Authors:  Hamideh Bashiri; Danielle J Houwing; Judith R Homberg; Ali-Akbar Salari
Journal:  Sci Rep       Date:  2021-04-19       Impact factor: 4.379

9.  Self-soothing behaviors with particular reference to oxytocin release induced by non-noxious sensory stimulation.

Authors:  Kerstin Uvnäs-Moberg; Linda Handlin; Maria Petersson
Journal:  Front Psychol       Date:  2015-01-12

10.  The Relationship between the Serum Oxytocin Levels, Disease Activity, the ADLs and the QOL in Patients with Rheumatoid Arthritis.

Authors:  Yusuke Miwa; Hidekazu Furuya; Ryo Yanai; Tsuyoshi Kasama; Kenji Sanada
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.